Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
UTHR

UTHR - United Therapeutics Corp Stock Price, Fair Value and News

306.04USD+8.98 (+3.02%)Market Closed

Market Summary

UTHR
USD306.04+8.98
Market Closed
3.02%

UTHR Alerts

  • 5 major insider sales recently.
  • Big jump in Revenue (Y/Y)

UTHR Stock Price

View Fullscreen

UTHR RSI Chart

UTHR Valuation

Market Cap

13.6B

Price/Earnings (Trailing)

12.92

Price/Sales (Trailing)

5.43

EV/EBITDA

8.24

Price/Free Cashflow

18.04

UTHR Price/Sales (Trailing)

UTHR Profitability

EBT Margin

55.28%

Return on Equity

19.68%

Return on Assets

16.17%

Free Cashflow Yield

5.54%

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

33.7%

Rev. Growth (Qtr)

10.25%

UTHR Earnings

Earnings (TTM)

1.1B

Earnings Growth (Yr)

27.27%

Earnings Growth (Qtr)

41.23%

Breaking Down UTHR Revenue

Last 7 days

11.0%

Last 30 days

11.6%

Last 90 days

29.3%

Trailing 12 Months

32.9%

How does UTHR drawdown profile look like?

UTHR Financial Health

Current Ratio

3.77

UTHR Investor Care

Buy Backs (1Y)

5.32%

Diluted EPS (TTM)

21.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.5B000
20232.0B2.1B2.2B2.3B
20221.8B1.8B1.9B1.9B
20211.5B1.6B1.7B1.7B
20201.4B1.4B1.4B1.5B
20191.6B1.5B1.5B1.4B
20181.7B1.7B1.7B1.6B
20171.6B1.6B1.7B1.7B
20161.5B1.6B1.6B1.6B
20151.3B1.3B1.4B1.5B
20141.2B1.2B1.2B1.3B
2013957.0M1.0B1.1B1.1B
2012784.9M826.7M867.4M916.1M
2011629.5M678.5M711.7M743.2M
2010405.1M455.8M527.2M592.9M
20090307.3M333.1M358.9M
2008000281.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of United Therapeutics Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 17, 2024
patusky christopher
acquired
152,720
76.36
2,000
-
Jun 17, 2024
olian judy d.
sold
-502,225
295
-1,700
-
Jun 17, 2024
patusky christopher
sold
-591,000
295
-2,000
-
Jun 14, 2024
rothblatt martine a
sold
-1,033,980
287
-3,600
chairperson & ceo
Jun 14, 2024
rothblatt martine a
acquired
466,164
129
3,600
chairperson & ceo
Jun 13, 2024
rothblatt martine a
sold
-1,027,720
285
-3,600
chairperson & ceo
Jun 13, 2024
rothblatt martine a
acquired
466,164
129
3,600
chairperson & ceo
Jun 13, 2024
causey christopher
sold
-563,055
281
-2,000
-
Jun 13, 2024
causey christopher
acquired
224,280
112
2,000
-
Jun 12, 2024
rothblatt martine a
acquired
466,164
129
3,600
chairperson & ceo

1–10 of 50

Which funds bought or sold UTHR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
10.64
3,701
24,371
-%
Jun 07, 2024
Railway Pension Investments Ltd
unchanged
-
95,351
2,228,280
0.02%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-1.56
1,775,000
22,392,000
0.04%
May 29, 2024
Clean Yield Group
unchanged
-
2,949
68,916
0.03%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
148,000
3,460,000
0.03%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
reduced
-76.89
-79,398,400
25,269,200
0.12%
May 24, 2024
Cetera Investment Advisers
added
113
718,743
1,303,430
-%
May 22, 2024
Beck Bode, LLC
new
-
1,838,970
1,838,970
0.38%
May 22, 2024
BURNEY CO/
added
119
2,904,430
5,156,980
0.20%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.27
880,669
2,076,670
0.26%

1–10 of 45

Are Funds Buying or Selling UTHR?

Are funds buying UTHR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own UTHR
No. of Funds

Unveiling United Therapeutics Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 10, 2024
vanguard group inc
10.57%
4,687,393
SC 13G/A
Feb 14, 2024
rothblatt martine a
7.8%
3,900,308
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
6.1%
2,858,888
SC 13G/A
Feb 13, 2024
renaissance technologies llc
4.62%
2,170,214
SC 13G/A
Feb 13, 2024
vanguard group inc
9.95%
4,673,678
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
8.07%
3,794,010
SC 13G/A
Jan 24, 2024
blackrock inc.
11.3%
5,294,844
SC 13G/A
Jul 10, 2023
wellington management group llp
10.01%
4,688,824
SC 13G/A
Mar 08, 2023
blackrock inc.
10.2%
4,726,986
SC 13G/A

Recent SEC filings of United Therapeutics Corp

View All Filings
Date Filed Form Type Document
Jun 18, 2024
144
Notice of Insider Sale Intent
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 17, 2024
144
Notice of Insider Sale Intent
Jun 17, 2024
144
Notice of Insider Sale Intent
Jun 17, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to United Therapeutics Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.86
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.7M
2.1M
16.67% 230.00%
-0.85
7.61
-13.45% 69.54%

United Therapeutics Corp News

Latest updates
MarketBeat5 hours ago

United Therapeutics Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue10.2%678615609597507492516467462415445447379385380362356311402374363
Costs and Expenses-9.4%3213552822832233162022651742452162244443201592221902482181521,019
  S&GA Expenses9.2%14413212813087.0016398.0014279.00128109113---------
  R&D Expenses-31.2%10415185.0089.0083.0094.0066.0094.0069.0083.0079.0074.0030412669.0090.0073.0011486.0086.00897
EBITDA Margin0.4%0.60*0.60*0.57*0.58*0.52*0.53*0.53*0.49*0.53*0.39*0.38*0.41*---------
Interest Expenses-11.9%13.0015.0016.0015.0014.0012.009.006.005.005.005.005.005.005.005.006.008.0010.0012.0012.0010.00
Income Taxes17.5%92.0078.0084.0076.0051.0047.0073.0035.0069.0028.0042.0044.004.0016.0048.0027.0034.0016.0035.0045.00-156
Earnings Before Taxes34.9%39929535233529217931315130914120421733.0011421913417268.00167250-650
EBT Margin1.0%0.55*0.55*0.53*0.53*0.47*0.49*0.49*0.45*0.49*0.35*0.34*0.37*---------
Net Income41.2%30721726825924113223911624011216317328.0099.0017110713853.00132205-494
Net Income Margin-0.6%0.42*0.42*0.41*0.41*0.37*0.38*0.38*0.35*0.39*0.28*0.28*0.30*---------
Free Cashflow369.9%33872.0028162.0033489.00190110275104162132---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-9.4%6,4957,1677,0246,6816,3466,0455,7825,5435,3605,1695,0494,8454,6414,6154,4114,2194,0263,9134,0003,8993,727
  Current Assets-8.5%3,2493,5513,4593,2133,1933,3803,0562,6842,5872,3242,3862,3182,0142,1671,8681,8941,8461,8651,9332,1401,943
    Cash Equivalents3.6%1,2521,2081,1081,0671,164961967795813895909942832739670685875738720881791
  Inventory7.5%12011210410310310291.0090.0088.0094.0097.0090.0092.0087.0088.0090.0092.0093.0094.0097.0096.00
  Net PPE2.7%1,0741,045992939897862841791784781727716714732736744739739678709701
Liabilities-2.1%1,1571,1821,3121,2701,2231,2481,2191,2251,1841,2101,2191,2051,1961,2201,1281,1261,0771,1331,2841,3321,389
  Current Liabilities7.0%861804744370325343316332293305320311302323259255207463470464270
Shareholder's Equity-10.8%5,3385,9855,7125,4115,1234,7974,5624,3184,1763,9593,8303,6403,4453,3953,2833,0942,9492,7802,7162,5582,319
  Retained Earnings5.1%6,3346,0275,8105,5425,2835,0424,9104,6714,5554,3154,2034,0403,8683,8393,7403,5693,4623,3253,2733,1402,935
  Additional Paid-In Capital-5.6%2,4052,5492,5242,4982,4572,3882,3152,2922,2542,2452,2262,1972,1732,1492,1262,1052,0682,0482,0262,0021,968
Shares Outstanding-6.0%44.0047.0047.0047.0046.0046.0046.0045.0045.0045.0045.0045.00---------
Float----9,138---10,532---7,912---4,726---2,977-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations149.8%376,500150,700346,200106,300374,800128,200258,600127,000288,700174,600185,600148,20089,800126,200250,900164,000214,600102,500185,400132,900-627,400
  Share Based Compensation54.2%25,60016,60021,10013,800-12,40064,800-2,40065,500-21,10044,70024,60029,10040,10093,700-12,50051,80030,80029,50023,900-37,20029,200
Cashflow From Investing1646.6%735,30042,100-313,400-227,200-221,100-189,300-94,000-169,000-359,200-195,800-235,900-48,900-6,300-63,800-271,700-375,400-27,60066,200-298,700-42,600-60,300
Cashflow From Financing-1050.9%-1,068,000-92,8007,60024,70048,60055,5007,00023,900-11,0007,50016,60010,60010,1006,1005,60021,600-50,200-150,000-48,300400809,100
  Buy Backs-1,000,000--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

UTHR Income Statement

2024-03-31
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Total revenues$ 677.7$ 506.9
Operating expenses:  
Cost of sales72.952.3
Research and development104.182.9
Selling, general, and administrative144.487.3
Total operating expenses321.4222.5
Operating income356.3284.4
Interest income53.829.2
Interest expense(13.3)(13.8)
Other income (expense), net1.8(7.9)
Total other income, net42.37.5
Income before income taxes398.6291.9
Income tax expense(92.0)(51.0)
Net income$ 306.6$ 240.9
Net income per common share:  
Basic (in dollars per share)$ 6.52$ 5.20
Diluted (in dollars per share)$ 6.17$ 4.86
Weighted average number of common shares outstanding:  
Basic (in shares)47.046.3
Diluted (in shares)49.749.6

UTHR Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 1,251.5$ 1,207.7
Marketable investments1,456.31,786.4
Accounts receivable, no allowance for 2024 and 2023307.3278.9
Inventories, net120.2111.8
Other current assets113.4166.2
Total current assets3,248.73,551.0
Marketable investments1,491.91,909.8
Goodwill and other intangible assets, net115.4114.2
Property, plant, and equipment, net1,074.01,045.4
Deferred tax assets, net396.1394.8
Other non-current assets169.1151.8
Total assets6,495.27,167.0
Current liabilities:  
Accounts payable and accrued expenses305.1298.0
Line of credit (current)400.0400.0
Share tracking awards plan29.235.4
Other current liabilities126.371.0
Total current liabilities860.6804.4
Line of credit (non-current)200.0300.0
Other non-current liabilities96.577.8
Total liabilities1,157.11,182.2
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued0.00.0
Common stock, par value $.01, 245,000,000 shares authorized, 74,098,932 and 73,659,761 shares issued, and 44,204,517 and 47,040,545 shares outstanding as of March 31, 2024 and December 31, 2023, respectively0.70.7
Additional paid-in capital2,405.42,549.0
Accumulated other comprehensive loss(15.6)(12.8)
Treasury stock, 29,894,415 and $26,619,216 shares as of March 31, 2024 and December 31, 2023, respectively(3,386.1)(2,579.2)
Retained earnings6,333.76,027.1
Total stockholders’ equity5,338.15,984.8
Total liabilities and stockholders’ equity$ 6,495.2$ 7,167.0
UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
 CEO
 WEBSITEunither.com
 INDUSTRYBiotechnology
 EMPLOYEES985

United Therapeutics Corp Frequently Asked Questions


What is the ticker symbol for United Therapeutics Corp? What does UTHR stand for in stocks?

UTHR is the stock ticker symbol of United Therapeutics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of United Therapeutics Corp (UTHR)?

As of Tue Jun 18 2024, market cap of United Therapeutics Corp is 13.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UTHR stock?

You can check UTHR's fair value in chart for subscribers.

What is the fair value of UTHR stock?

You can check UTHR's fair value in chart for subscribers. The fair value of United Therapeutics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of United Therapeutics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UTHR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is United Therapeutics Corp a good stock to buy?

The fair value guage provides a quick view whether UTHR is over valued or under valued. Whether United Therapeutics Corp is cheap or expensive depends on the assumptions which impact United Therapeutics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTHR.

What is United Therapeutics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, UTHR's PE ratio (Price to Earnings) is 12.92 and Price to Sales (PS) ratio is 5.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTHR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on United Therapeutics Corp's stock?

In the past 10 years, United Therapeutics Corp has provided 0.133 (multiply by 100 for percentage) rate of return.